Table 3.
Cannabinoids (subtypes CB1 and CB2) and opioids receptors (subtypes δ, κ, and μ) binding affinity assay of the secondary metabolites isolated from R. alpinia. Concentration Tested (10 μM).
| Compound | Cannabinoid receptors (%)
|
Opioid receptors (%)
|
|||
|---|---|---|---|---|---|
| CB1 | CB2 | δ Delta | κ Kappa | μ Mu | |
| 1 | – | 6.6 | – | – | – |
| 2 | – | 2.5 | – | 14.9 | – |
| 3 | 9.3 | 3.4 | – | 13.3 | 4.4 |
| 4 | 33.3 | 16.7 | 2.8 | 23.7 | 37.4 |
| 5 | – | – | – | 33.5 | 32.0 |
| 6 | – | 7. 8 | – | – | 12.7 |
| AM251 | 97.6 | 83.3 | – | – | – |
| AM630 | 77.6 | 95.9 | – | – | – |
| Naloxone | – | – | 99.3 | 98.9 | 99.8 |
AM-251 is an inverse agonist at the CB1 cannabinoid receptor; AM-630 (6-Iodopravadoline) is a compound that acts as a potent and selective inverse agonist for the cannabinoid receptor CB2.